Anti-viral therapy using lamivudine and thymosin is helpful to prevent recurrence in hepatocellular carcinoma with coexisting active hepatitis B / 中华肿瘤杂志
Zhonghua zhong liu za zhi
; (12): 114-116, 2005.
Article
en Zh
| WPRIM
| ID: wpr-331214
Biblioteca responsable:
WPRO
ABSTRACT
<p><b>OBJECTIVE</b>To observe the effect of postoperative anti-viral therapy using lamivudine and thymosin alpha1 on recurrence of hepatocellular carcinoma (HCC) coexisting with active hepatitis B.</p><p><b>METHODS</b>From Jan. 2000 to Dec. 2002, 33 HCC patients with coexisting with active hepatitis B were randomized into two groups: Group I (n = 17) received hepatectomy only, and Group II (n = 16) received hepatectomy and postoperative therapy using lamivudine plus thymosin alpha1. The suppression of HBV-DNA, HBeAg seroconversion rate, tumor recurrence rate and median survival in the two groups were observed and compared.</p><p><b>RESULTS</b>In Group II and Group I, the 1-year HBV-DNA suppression rate was 100.0% vs 6.0% (P < 0.01), HBeAg seroconversion rate was 62.5% vs 5.9% (P < 0.05), tumor recurrence rate was 81.3% vs 95.5% (P > 0.05), the recurrence time was 7.0 vs 5.0 months (P < 0.01) and median survival 10.0 vs 7.0 months (P < 0.01).</p><p><b>CONCLUSION</b>Anti-viral therapy using lamivudine and thymosin alpha1 postoperatively may suppress the HBV reaction, delay the recurrence and prolong the survival for patients with HCC with coexisting active hepatitis B.</p>
Texto completo:
1
Base de datos:
WPRIM
Asunto principal:
Periodo Posoperatorio
/
Cirugía General
/
Terapéutica
/
Timosina
/
Virología
/
ADN Viral
/
Tasa de Supervivencia
/
Carcinoma Hepatocelular
/
Inhibidores de la Transcriptasa Inversa
/
Lamivudine
Tipo de estudio:
Clinical_trials
Límite:
Adult
/
Aged
/
Female
/
Humans
/
Male
Idioma:
Zh
Revista:
Zhonghua zhong liu za zhi
Año:
2005
Tipo del documento:
Article